Zacks Research Raises Earnings Estimates for Editas Medicine

Editas Medicine, Inc. (NASDAQ:EDIT) – Stock analysts at Zacks Research upped their Q1 2025 earnings estimates for Editas Medicine in a research note issued on Wednesday, March 26th. Zacks Research analyst A. Chakraborty now expects that the company will post earnings per share of ($0.63) for the quarter, up from their prior forecast of ($0.73). The consensus estimate for Editas Medicine’s current full-year earnings is ($2.71) per share. Zacks Research also issued estimates for Editas Medicine’s Q2 2025 earnings at ($0.66) EPS, Q3 2025 earnings at ($0.65) EPS, Q4 2025 earnings at ($0.68) EPS, FY2025 earnings at ($2.62) EPS, Q1 2026 earnings at ($0.63) EPS, Q2 2026 earnings at ($0.62) EPS and Q4 2026 earnings at ($0.60) EPS.

Other analysts have also issued research reports about the stock. Royal Bank of Canada cut their price objective on shares of Editas Medicine from $5.00 to $4.00 and set a “sector perform” rating on the stock in a research report on Friday, December 13th. Robert W. Baird lowered their price objective on shares of Editas Medicine from $10.00 to $8.00 and set an “outperform” rating on the stock in a research note on Friday, December 13th. Stifel Nicolaus lowered Editas Medicine from a “buy” rating to a “hold” rating and decreased their target price for the stock from $11.00 to $3.00 in a report on Friday, December 13th. JPMorgan Chase & Co. cut shares of Editas Medicine from a “neutral” rating to an “underweight” rating in a report on Monday, December 16th. Finally, Truist Financial cut Editas Medicine from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Three analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, Editas Medicine has an average rating of “Hold” and a consensus price target of $6.83.

Editas Medicine Price Performance

Shares of Editas Medicine stock opened at $1.25 on Monday. The firm has a market cap of $103.72 million, a price-to-earnings ratio of -0.49 and a beta of 1.88. The stock’s 50-day moving average is $1.51 and its 200-day moving average is $2.16. Editas Medicine has a one year low of $1.12 and a one year high of $7.41.

Editas Medicine (NASDAQ:EDIT) last posted its earnings results on Wednesday, March 5th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.16). The business had revenue of $30.60 million for the quarter, compared to the consensus estimate of $37.17 million. Editas Medicine had a negative return on equity of 80.13% and a negative net margin of 340.96%. During the same period in the previous year, the company posted ($0.23) earnings per share.

Institutional Investors Weigh In On Editas Medicine

A number of large investors have recently bought and sold shares of EDIT. Ieq Capital LLC bought a new stake in Editas Medicine during the fourth quarter worth $31,000. Thrive Wealth Management LLC bought a new stake in shares of Editas Medicine in the fourth quarter worth $36,000. Dark Forest Capital Management LP raised its position in Editas Medicine by 66.9% during the 4th quarter. Dark Forest Capital Management LP now owns 32,787 shares of the company’s stock worth $42,000 after purchasing an additional 13,138 shares during the last quarter. Freestone Grove Partners LP bought a new position in shares of Editas Medicine during the fourth quarter worth about $46,000. Finally, Y Intercept Hong Kong Ltd acquired a new position in shares of Editas Medicine in the third quarter worth approximately $47,000. 71.90% of the stock is currently owned by institutional investors and hedge funds.

About Editas Medicine

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.